Mgliche Risikogruppen fr L-Carnitin-Mangel Das Risiko, einen L-Carnitin-Mangel zu entwickeln, ist vor allem bei Tumorpatienten, bei Menschen mit Diabetes, aber auch bei Vegetariern und bei Dialysepatienten sowie Personen mit eingeschrnkter Leber- und Nierenfunktion erhht
In AD, cerebrovascular dysfunction occurs earlier among E4 carriers (Veitch et al., 2019), which could lead to impairments in nutrient sensing and metabolite exchange between the brain and periphery, thereby negatively impacting brain bioenergetics by rendering brain areas of high energetic needs (e.g., the hippocampus) vulnerable to pathologies such as amyloid (Veitch et al., 2019
Report of a WHO consultation
This compound is not FDA-approved for clinical or therapeutic use and is not intended to diagnose, treat, cure, or prevent any disease or condition .
Presented for research literature review only Ribas V et al